MedTrace Logo

Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

NCT05049447 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-20

No results posted yet for this study

Summary

Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.

Conditions

  • Stress
  • Brain Activity
  • Passiflora Incarnata
  • Test Anxiety

Interventions

DRUG

Pascoflair

1 x 2 tablets (single-dose)

OTHER

Placebo

1 x 2 tablets (single-dose)

Sponsors & Collaborators

  • NeuroCode AG

    collaborator UNKNOWN

  • Pascoe Pharmazeutische Praeparate GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05049447 on ClinicalTrials.gov